Brief: Aeterna Zentaris Provides Update On Ongoing Pivotal Phase 3 Detect-Trial For Diagnosis Of Childhood-Onset Growth Hormone Deficiency

COSCIENS Biopharma

21/03/2022 13:42

March 21 (Reuters) - Aeterna Zentaris Inc  AEZS.TO :
    * AETERNA ZENTARIS PROVIDES UPDATE ON ONGOING PIVOTAL PHASE
3
DETECT-TRIAL FOR DIAGNOSIS OF CHILDHOOD-ONSET GROWTH HORMONE
DEFICIENCY
    * AETERNA ZENTARIS INC - PATIENT ENROLLMENT EXPECTED TO
CONTINUE
INTO 2023
    * AETERNA ZENTARIS INC - CLINICAL TRIAL SITES ORIGINALLY
PLANNED
IN UKRAINE AND RUSSIA ARE BEING HALTED DUE TO CONFLICT IN
UKRAINE
    * AETERNA ZENTARIS INC - SITE ACTIVATION AND PATIENT
ENROLLMENT
CONTINUES TO BE IMPACTED BY ONGOING COVID-19 PANDEMIC
    * AETERNA ZENTARIS INC - FURTHER DELAYS WITH ENROLLMENT ARE
EXPECTED AS DETECT-TRIAL PLANNED TO RECRUIT AT LEAST 25% WITHIN
UKRAINE AND RUSSIA
    * AETERNA ZENTARIS INC - CO AND NOVO NORDISK, ARE ACTIVELY
ASSESSING FULL IMPACT OF CURRENT SITUATION IN UKRAINE ON
TIMELINES AND STUDY COST

Source text for Eikon:  ID:nGNXbRPytt 
Further company coverage:  AEZS.TO 

 ((Reuters.Briefs@thomsonreuters.com;))